Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0T6G stock hub

LON/0T6G has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0T6Gis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

66.8M

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0T6G

In the news

Latest news · LON/0T6G

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/E2.7

P25 15.9P50 22.9P75 35.8

ROE157.2

P25 -54.2P50 2.1P75 13.7

ROIC36.1

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0T6G market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

160

Groups with data

Currency

USD

Showing 160 of 160 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	UK
Employees	24
Employees Change	-17%
Employees Change Percent	-39.53
Enterprise value	$39.1M
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	US7469641051
Last refreshed	2026-05-10
Market cap	$66.8M
Price	$5.36
Price currency	USD
Rev Per Employee	1,695,637.46x
Sector	Healthcare
Sic	2836
Symbol	lon/0T6G
Website	https://www.q32bio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	37.67%
EV Earnings	1.55x
EV/EBIT	2.49x
EV/EBITDA	2.26x
EV/Sales	0.99x
P/B ratio	1.91x
P/E ratio	2.65x
P/S ratio	1.64x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	39.84%
EBITDA Margin	40.51%
Gross margin	64.35%
Gross Profit	$26.2M
Net Income	$25.2M
Net Income Growth Quarters	3%
Net Income Growth Years	2%
Pretax Margin	61.86%
Profit Margin	61.86%
Profit Per Employee	$1M
Profitable Years	1
ROA	18.75
ROCE	40.39
ROE	157.2
ROIC	36.15

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	240.41%
EPS Growth Quarters	3
EPS Growth Years	2
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.75
Assets	$48.2M
Cash	$38.4M
Current Assets	$40.4M
Current Liabilities	$8.3M
Debt	$9.8M
Debt EBITDA	$0.55
Debt Equity	$0.28
Equity	$35.1M
Interest Coverage	19.46
Liabilities	$13.1M
Long Term Assets	$7.8M
Long Term Liabilities	$4.8M
Net Cash	$28.6M
Net Cash By Market Cap	$42.86
Net Cash Growth	-44.21%
Net Debt EBITDA	$-1.74
Net Debt Equity	$-0.82
Tangible Book Value	$35.1M
Tangible Book Value Per Share	$2.4
WACC	-0.31

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.36
Net Working Capital	$1.5M
Quick ratio	4.76
Working Capital	$35.2M
Working Capital Turnover	$0.75

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-27.51%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	240.12%
200-day SMA	3.55
50-day SMA	5.88
50-day SMA vs 200-day SMA	50over200
All Time High	53.4
All Time High Change	-89.96%
All Time High Date	2024-09-11
All Time Low	1.32
All Time Low Change	306.06%
All Time Low Date	2025-07-10
ATR	0.57
Beta	-1.02
Ch YTD	68.29
High	5.51
High52	8.02
High52 Date	2026-03-27
High52ch	-33.17%
Low	5.35
Low52	1.32
Low52 Date	2025-07-10
Low52ch	306.06%
Ma50ch	-8.81%
Price vs 200-day SMA	51.11%
RSI	44.55
RSI Monthly	46.69
RSI Weekly	54.32
Sharpe ratio	1.42x
Sortino ratio	3.07
Total Return	-27.51%
Tr YTD	68.32
Tr1m	-9.46%
Tr1w	2.37%
Tr3m	21.54%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$16.2M
Operating margin	39.84

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	6,403,253%
Net Borrowing	-2,292,231.3
Shares Insiders	0.71%
Shares Institutions	13.6%
Shares Qo Q	2.88%
Shares Yo Y	27.51%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	2,249.7x
Bv Per Share	2.4
Ch1m	-9.46
Ch1w	2.37
Ch1y	240.1
Ch3m	21.54
Ch6m	145.9
Change	-2.81%
Change From Open	-0.74
Close	5.52
Days Gap	-2.17
Depreciation Amortization	286,804
Dollar Volume	6,549.9
Earnings Date	2026-05-14
EBIT	$16.2M
EBITDA	$16.5M
EPS	$1.97
F Score	4
Financing CF	4,295,434
Fiscal Year End	December
Founded	2,017
Graham Number	11.30564
Graham Upside	110.9
Investing CF	5,301,135
Is Primary Listing	0
Last Earnings Date	2025-11-06
Last Report Date	2025-12-31
Ma150	4.1
Ma150ch	30.7%
Ma20	5.71
Ma20ch	-6.06%
Net CF	-11,156,617
Next Earnings Date	2026-05-14
Open	5.4
Position In Range	6.25
Ppne	4,459,031.6
Price Date	2026-05-08
Price EBITDA	$4.05
Ptbv Ratio	1.91
Relative Volume	0.58x
Revenue	40,695,299x
SBC By Revenue	10.16x
Share Based Comp	4,135,643
Tr6m	145.86%
Volume	1,222

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0T6G pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0T6G stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0T6G?

Insider, institutional, and short-interest positioning.

Institutional ownership

+13.6%

Share of float held by funds and institutions

Insider ownership

+0.7%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+27.5%

Negative means the company is buying back shares.

Technical

LON/0T6G momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

44.5

Neutral momentum band

Price vs 200-day MA

+51.1%

50/200-day relationship not available

Beta (5Y)

-1.02

Less volatile than the market

Sharpe ratio

1.42

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0T6G

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0T6G stock rating?

lon/0T6G is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0T6G analysis?

The full report lives at /stocks/lon/0T6G/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0T6G?

The latest report frames lon/0T6G around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0T6G page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.